News
FDA backs Astellas/Seattle Genetics bladder cancer drug
The FDA has quickly okayed Astellas and Seattle Genetics’ advanced bladder cancer drug enfortumab vedotin, one of the stars of this year’s ASCO conference that was considered an almost dead
